NAS:JAZZ (Ireland)
Business Description
Jazz Pharmaceuticals PLC
NAICS : 325412
SIC : 2834
Waterloo Road, Fifth Floor, Waterloo Exchange, Dublin, IRL, D04 E5W7
Compare
Compare
Traded in other countries / regions
J7Z.Germany
•
JAZZ.Mexico
•
JAZZ.USA
Description
Jazz Pharmaceuticals is an Ireland-domiciled biopharmaceutical firm focused primarily on treatments for sleeping disorders and oncology. Jazz has nine approved drugs across neuroscience and oncology indications; its portfolio includes Xyrem and Xywav for narcolepsy, Zepzelca for the treatment of metastatic small cell lung cancer, Rylaze for acute lymphoblastic leukemia, and Vyxeos for acute myeloid leukemia. In May 2021, Jazz acquired GW Pharmaceuticals and gained its leading product, Epidiolex for the treatment of severe, rare forms of epilepsy.
Financial Strength
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 0.13 | |||||
| Equity-to-Asset | 0.29 | |||||
| Debt-to-Equity | 1.91 | |||||
| Debt-to-EBITDA | 6.8 | |||||
| Interest Coverage | 1.01 | |||||
| Piotroski F-Score | 4/9 | |||||
| Altman Z-Score | 1.44 | |||||
| Beneish M-Score | -2.7 | |||||
| WACC vs ROIC | ||||||
Growth Rank
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | 18.8 | |||||
| 3-Year EBITDA Growth Rate | -3.7 | |||||
| 3-Year FCF Growth Rate | 4 | |||||
| 3-Year Book Growth Rate | 10.3 | |||||
| Future 3-5Y EPS without NRI Growth Rate Industry Rank | -2.03 | |||||
| Future 3-5Y Total Revenue Growth Rate Industry Rank | 9.16 |
Momentum Rank
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 60.48 | |||||
| 9-Day RSI | 55.8 | |||||
| 14-Day RSI | 54 | |||||
| 6-1 Month Momentum % | 8.84 | |||||
| 12-1 Month Momentum % | 6.08 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 3.67 | |||||
| Quick Ratio | 2.45 | |||||
| Cash Ratio | 1.09 | |||||
| Days Inventory | 744.06 | |||||
| Days Sales Outstanding | 57.36 | |||||
| Days Payable | 52.76 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -2.3 |
Profitability Rank
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 85.04 | |||||
| Operating Margin % | 9.19 | |||||
| Net Margin % | -1.49 | |||||
| ROE % | -1.38 | |||||
| ROA % | -0.43 | |||||
| ROIC % | 1.33 | |||||
| ROC (Joel Greenblatt) % | 14.01 | |||||
| ROCE % | 2.02 | |||||
| Years of Profitability over Past 10-Year | 9 |
GF Value Rank
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Forward PE Ratio | 8.91 | |||||
| Shiller PE Ratio | 32.53 | |||||
| Price-to-Owner-Earnings | 91.33 | |||||
| PS Ratio | 2.81 | |||||
| PB Ratio | 3.07 | |||||
| Price-to-Free-Cash-Flow | 12.09 | |||||
| Price-to-Operating-Cash-Flow | 10.16 | |||||
| EV-to-EBIT | 65.83 | |||||
| EV-to-Forward-EBIT | 15.13 | |||||
| EV-to-EBITDA | 16.9 | |||||
| EV-to-Forward-EBITDA | 11.11 | |||||
| EV-to-Revenue | 4.36 | |||||
| EV-to-Forward-Revenue | 4.19 | |||||
| EV-to-FCF | 18.78 | |||||
| Price-to-Projected-FCF | 0.9 | |||||
| Price-to-DCF (FCF Based) | 0.43 | |||||
| Price-to-Median-PS-Value | 0.49 | |||||
| Earnings Yield (Greenblatt) % | 1.52 | |||||
| Forward Rate of Return (Yacktman) % | 9.38 |
Guru Trades
See DetailsEMBED
SAVE
Insider Trades
See DetailsEMBED
SAVE
Gurus Latest Trades with NAS:JAZZ
Executives
EMBED
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 3,481.445 | ||
| EPS (TTM) ($) | -0.85 | ||
| Beta | 0.62 | ||
| Volatility % | 32.51 | ||
| 14-Day RSI | 54 | ||
| 14-Day ATR ($) | 4.358694 | ||
| 20-Day SMA ($) | 155.8065 | ||
| 12-1 Month Momentum % | 6.08 | ||
| 52-Week Range ($) | 117.64 - 169.98 | ||
| Shares Outstanding (Mil) | 62.68 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 4 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Jazz Pharmaceuticals PLC Filings
| Document | Form | Filing Date | ||
|---|---|---|---|---|
| No Filing Data | ||||